The selective Janus kinase (JAK) 1 and JAK2 inhibitor ruxolitinib was approved by the PBS in February for use in patients with myelofibrosis1 Dr Lynette Chee, a consultant haematologist at the Royal Melbourne Hospital, describes its use in a 43-year-old woman with Intermediate-1 risk myelofibrosis. She also outlines the evidence around the drug and gives ...
A haematologists experience of ruxolitinib in Intermediate-1 myelofibrosis patients
By Dr Lynette Chee MBBS PhD FRACP FRCPA
14 Sep 2016
Sponsored by Novartis Oncology